H.C. Wainwright analyst Ananda Ghosh assumed coverage of Inventiva (IVA) with a Buy rating and $20 price target The FDA’s recent acceptance of the company’s letter of intent for liver stiffness measurement as a surrogate endpoint adds positive regulatory momentum for Inventiva, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVA:
- Inventiva price target raised to $13 from $9 at Guggenheim
- 3 Best Stocks to Buy Now, 8/28/2025, According to Top Analysts
- Inventiva initiated with an Overweight at Piper Sandler
- Inventiva’s Strategic Positioning and Promising Developments Drive Buy Rating
- Inventiva’s Strong Financial Position and Promising Phase 3 Trial Drive Buy Rating